Tag: Innovative Medicines

Small biotech companies rule in development of microbiome-targeted therapeutics

According to leading data and analytics company GlobalData, large pharma firms are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology,

Arbutus and Roivant create Genevant Sciences to focus on RNA-based therapeutics

Arbutus Biopharma Corporation and Roivant Sciences entered into an agreement to launch Genevant Sciences, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics.

State Duma deputies propose to simplify registration of Russian medicines

The issues of legislative regulation and simplification of drug registration procedures were discussed by participants of the roundtable held on April 9 in the Russian State Duma.

Ferring buys a clinical microbiome company Rebiotix

lab research
This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.

IFAR is developing a life-extending drug

The scientists from IFAR, a Tomsk-based Russian company, found a way to use plant materials for producing a substance that extends human life.

Vaxart will present its oral influenza vaccine development program

digital drug
Vaxart a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, completed the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine.

Three British biotech leaders will develop a new class of medicines

Three leading British biotechnology businesses (CHAIN Biotech, Porton Biopharma and Scitech) have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines.

Nemaura Pharma moves forward with unique transdermal drug delivery technology

UK biotech company Nemaura Pharma has made significant progress in the reformulation of liquid vaccines administered through the skin using its solid dose delivery system, Micro-Patch

Recipharm and Altus Formulation will work on novel drug delivery technologies

Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation to allow its customers to access new drug delivery technologies and products.

First diabetes pill from Novo Nordisk shows solid results in clinical trials

Novo Nordisk today announced the headline results from the first phase 3a trial with oral semaglutide. First ever diabetes pill can change whole diabetes market replacing injection for blood sugar control.

Rani Therapeutics received funding for clinicals trials of its innovative pill

digital drug
Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery, announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials

Moderna Therapeutics raised $500 million funding for drug development

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering mRNA therapeutics and vaccines, raised $500 million in a new funding round

Cannabinoid-based epilepsy drug from GW Pharmaceuticals shows promising results

medicinal cannabis
GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from its proprietary cannabinoid product platform, announced that The Lancet has published results from a Phase 3 study of Epidiolex

The Helmholtz Association establishes innovative antibody production

The Helmholtz Association, the largest scientific organisation in Germany, is funding a new Helmholtz Zentrum München spin-off with roughly 115,000 euros

Sechenov University will develop drugs for the treatment of malaria

Sechenov University has passed the competitive selection for receiving the subsidy under the Federal Target-Oriented Program

DelSiTech and C-Tri will develop a novel drug delivery technology

DelSiTech Ltd and C-Tri Co. Ltd have signed a Partnership and Collaboration Agreement to develop long-acting controlled release formulations